BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15273706)

  • 1. A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone.
    Karanth M; Chakrabarti S; Lovell RA; Harvey C; Holder K; McConkey CC; McDonald D; Fegan CD; Milligan DW
    Bone Marrow Transplant; 2004 Sep; 34(5):399-403. PubMed ID: 15273706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.
    Jantunen E; Putkonen M; Nousiainen T; Pelliniemi TT; Mahlamäki E; Remes K
    Bone Marrow Transplant; 2003 Mar; 31(5):347-51. PubMed ID: 12634725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF.
    Meldgaard Knudsen L; Jensen L; Gaarsdal E; Nikolaisen K; Johnsen HE
    Bone Marrow Transplant; 2000 Oct; 26(7):717-22. PubMed ID: 11042651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
    Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
    Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
    McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
    Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
    Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
    Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors.
    Fischer JC; Frick M; Wassmuth R; Platz A; Punzel M; Wernet P
    Br J Haematol; 2005 Sep; 130(5):740-6. PubMed ID: 16115131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF.
    Haynes A; Hunter A; McQuaker G; Anderson S; Bienz N; Russell NH
    Bone Marrow Transplant; 1995 Sep; 16(3):359-63. PubMed ID: 8535307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
    Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
    Suh C; Kim HJ; Kim SH; Kim S; Lee SJ; Lee YS; Kim EK; Kim SB; Lee JS; Kim MW; Kim K; Yoon SS
    Transfusion; 2004 Apr; 44(4):533-8. PubMed ID: 15043569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of the addition of methylprednisolone to intermediate-dose cyclophosphamide and lenograstim for stem cell mobilization to make the timing of PBSC harvesting more predictable.
    Rudin CE; Melhuish J; Hall J
    Bone Marrow Transplant; 2007 Aug; 40(3):293-4. PubMed ID: 17529998
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
    Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy.
    Weaver A; Testa NG
    Bone Marrow Transplant; 1998 Jul; 22(1):33-8. PubMed ID: 9678793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study.
    Basara N; Schmetzer B; Blau IW; Bischoff M; Günzelmann S; Kirsten D; Fauser AA
    Bone Marrow Transplant; 2000 Feb; 25(4):371-6. PubMed ID: 10723579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of concurrent G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease.
    Madero L; González-Vicent M; Molina J; Madero R; Quintero V; Díaz MA
    Bone Marrow Transplant; 2000 Aug; 26(4):365-9. PubMed ID: 10982281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study on single-dose rhG-CSF combined with chemotherapy in autologous peripheral blood stem cell transplantation].
    Tian H; Zhou SY
    Ai Zheng; 2002 Aug; 21(8):896-9. PubMed ID: 12478902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell mobilisation in lymphoproliferative diseases.
    Russell NH; McQuaker G; Stainer C; Byrne JL; Haynes AP
    Bone Marrow Transplant; 1998 Nov; 22(10):935-40. PubMed ID: 9849689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.